Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - metronidazole 500 mg/100 ml - solution for infusion - 5 mg/ml - metronidazole 5 mg/ml - metronidazole; p01ab01 metronidazole; g01af01 metronidazole

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - metronidazole 500 mg/100 ml - solution for infusion - 5 mg/ml - metronidazole 5 mg/ml - metronidazole; p01ab01 metronidazole; g01af01 metronidazole

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - metronidazole - solution for infusion - 0.5 percent weight/volume - imidazole derivatives; metronidazole

Singapura - Inggeris - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - metronidazole - injection - 0.5% w/v - metronidazole 0.5% w/v

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; macrogol 400; magnesium stearate; maize starch; povidone; calcium hydrogen phosphate - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: hypromellose; magnesium stearate; purified talc; calcium hydrogen phosphate; macrogol 400; maize starch; povidone - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 500 mg - suppository - excipient ingredients: hard fat - anaerobic infections: suppositories treatment of anaerobic infection in patients for whom oral medication is not possible or is contraindicated. prevention of anaerobic infection in high risk situations in patients for whom oral medication is not possible or is contraindicated. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia. note. metronidazole is inactive against aerobic and facultative anaerobic bacteria.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole benzoate, quantity: 64 mg/ml - oral liquid, suspension - excipient ingredients: ethanol; monobasic sodium phosphate; aluminium magnesium silicate; methyl hydroxybenzoate; sucrose; propyl hydroxybenzoate; orange oil terpeneless; flavour - anaerobic infections treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. notes. 1. because of the slow absorption and delayed peak plasma level, flagyl suspension is not recommended for use in the acute situation. 2. metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis( intestinal and extraintestin

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole; metronidazole benzoate -

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - metronidazole - infusion - 5mg/1ml